Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › osimertinib

osimertinib

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of osimertinib

13 trials tracked of osimertinib: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 5 citations.

13Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 2 8 Phase 1 2 Other / NA 2
  1. Phase 4 Osimertinib Study in Indian Patients Completed · 5 cited
  2. Phase 2 G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Completed
  3. Phase 2 Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M Completed
  4. Phase 2 A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib Completed
  5. Phase 2 Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M Completed
  6. Phase 2 A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations Completed
Show 7 more trials
  1. Phase 2 Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) Completed
  2. Phase 2 Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib Completed
  3. Phase 2 Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers Completed
  4. Phase 1 A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer Completed
  5. Phase 1 Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases Completed
  6. N/A Afatinib Osimertinib Sequencing NIS Completed
  7. N/A A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. Completed

Showing the 13 most-cited and recently-updated of 13 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review discusses osimertinib use in EGFR-mutated NSCLC patients with TKI resistance
Drug Pipeline Sys. Review
Narrative review discusses osimertinib use in EGFR-mutated NSCLC patients with TKI resistance Osimertinib may help some lung cancer patients after resistance develops
This narrative review examines the use of osimertinib and other EGFR-TKIs in non-small cell lung cancer patients harboring EGFR mutations af…
A review suggests osimertinib could be an option for non-small cell lung cancer patients with EGFR mutations who develop resistance to earli…
Frontiers Apr 22, 2026
Five medications including daptomycin and durvalumab show positive association with drug-induced eosinophilic pneumonia in database analysis
Rheumatology Cohort
Five medications including daptomycin and durvalumab show positive association with drug-induced eosinophilic pneumonia in database analysis 15,000 Cases Found: Which Drugs Harm Your Lungs?
A retrospective pharmacovigilance investigation analyzed 15,374 cases in FAERS and Vigibase databases to identify drug-induced eosinophilic …
A massive data review reveals which medicines might silently damage your lungs.
Frontiers Apr 22, 2026
Case Report Details Aumolertinib Rechallenge Following Osimertinib-Induced Interstitial Lung Disease in Lung Adenocarcinoma
Drug Pipeline Guideline
Case Report Details Aumolertinib Rechallenge Following Osimertinib-Induced Interstitial Lung Disease in Lung Adenocarcinoma Can lung cancer drugs be restarted after severe lung injury?
This case report describes a 73-year-old male with stage IV lung adenocarcinoma and EGFR exon 19 deletions who experienced interstitial lung…
Doctors successfully restarted a powerful lung cancer drug after a patient's lungs healed from a dangerous reaction to the first one.
Frontiers Apr 19, 2026
First-line osimertinib shows high response rates in EGFR-mutated NSCLC with active brain metastases
Pulmonology & Critical Care Phase II
First-line osimertinib shows high response rates in EGFR-mutated NSCLC with active brain metastases Untreated Brain Metastases Respond Well to Osimertinib
This single-arm phase II trial evaluated first-line osimertinib in 100 patients with EGFR-mutated non-small cell lung cancer, including thos…
Osimertinib, a lung cancer drug, effectively treats untreated brain metastases, with an 81.8% response rate for measurable brain spots in a …
Apr 13, 2026
Amivantamab-lazertinib shows OS benefit over osimertinib in Asian EGFR-mutant NSCLC subset
Pulmonology & Critical Care RCT
Amivantamab-lazertinib shows OS benefit over osimertinib in Asian EGFR-mutant NSCLC subset Combination therapy shows longer survival than standard drug in Asian lung cancer patients
In a subset analysis of an RCT of 629 Asian patients with untreated EGFR-mutant advanced NSCLC, amivantamab-lazertinib prolonged overall sur…
Asian lung cancer patients on a new two-drug combination therapy lived longer than those taking the standard single drug, with a 26% lower r…
Apr 1, 2026